四氢异葫芦素I | 3877-89-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 四氢异葫芦素I
• 英文名称: isocucurbitacin R
• 英文别名: 23,24-dihydroisocucurbitacin D；tetrahydro-isocucurbitacin I；dihydro-isocucurbitacin D；3α,16α,20,25-tetrahydroxy-10α-cucurbit-5-ene-2,11,22-trione；3α,16α,20,25-Tetrahydroxy-10α-cucurbit-5-en-2,11,22-trion；Tetrahydroisocucurbitacin I；(3S,8S,9R,10R,13R,14S,16R,17R)-17-[(2R)-2,6-dihydroxy-6-methyl-3-oxoheptan-2-yl]-3,16-dihydroxy-4,4,9,13,14-pentamethyl-3,7,8,10,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthrene-2,11-dione
• CAS: 3877-89-2
• 化学式: C₃₀H₄₆O₇
• 分子量: 518.691
• InChiKey: YQLCUPUXBKOMCZ-PYZGANRSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  37
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  132
• 氢给体数：
  4
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 palladium on activated charcoal 、 乙醇 作用下， 生成 四氢异葫芦素I
  参考文献：
  名称：

  Lavie; Benjaminov, Journal of Organic Chemistry, 1965, vol. 30, p. 607,609

  摘要：

  DOI：

文献信息

• Chemosensory receptor ligand-based therapies
  申请人：Anji Pharma (US) LLC

  公开号：US10610500B2

  公开（公告）日：2020-04-07

  Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory receptor ligand, such as a bitter receptor ligand. Also provided herein are chemosensory receptor ligand compositions, including bitter receptor ligand compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.

  本文提供了通过施用包含化感受体配体（如苦味受体配体）的组合物来治疗与化感受体相关的病症（包括糖尿病、肥胖症和其他代谢性疾病、失调或病症）的方法。本文还提供了化学感觉受体配体组合物，包括苦味受体配体组合物，及其用于本发明方法的制备方法。本文还提供了包含二甲双胍及其盐类的组合物和使用方法。
• The Constituents of Ecballium elaterium L. III. Elatericin A and B^1,2
  作者：David Lavie、David Willner

  DOI：10.1021/ja01536a047

  日期：1958.2
• Constituents of Citrullus colocynthis (L.) Schrad.
  作者：D. Lavie、D. Willner、Z. Merenlender

  DOI：10.1016/s0031-9422(00)83994-1

  日期：1964.1
• CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES
  申请人：Anji Pharma (US) LLC

  公开号：EP2661266B1

  公开（公告）日：2020-09-16
• Chemosensory Receptor Ligand-Based Therapies
  申请人：BARON Alain D.

  公开号：US20120177730A1

  公开（公告）日：2012-07-12

  Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory receptor ligand, such as a bitter receptor ligand. Also provided herein are chemosensory receptor ligand compositions, including bitter receptor ligand compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.